PT-141 dosage depends on the form: Vyleesi's FDA-approved 1.75 mg injection vs. off-label peptide and nasal spray dosing. See charts and safety notes.
The FDA-approved PT-141 dosage is 1.75 mg injected subcutaneously (Vyleesi) about 45 minutes before anticipated sexual activity. You should not exceed one dose in 24 hours or eight doses in a month. Research peptides and nasal spray forms of PT-141 are not FDA-approved and use different amounts studied in clinical trials.
What PT-141 Is and Why the Dose Depends on the Form
PT-141 is the research name for bremelanotide, a melanocortin receptor agonist. Vyleesi is the only FDA-approved bremelanotide product, and it comes as a prefilled autoinjector. The peptide sold for research arrives as a lyophilized powder that must be reconstituted, while nasal sprays remain experimental.
Dose depends on route because the body absorbs injected and intranasal bremelanotide differently. The approved injectable dose is fixed, while off-label research doses range from about 1 mg to 2 mg subcutaneously in most user reports.
FDA-Approved PT-141 Dosage (Vyleesi)
Vyleesi is approved for premenopausal women with hypoactive sexual desire disorder (HSDD). The Vyleesi dosage is 1.75 mg injected under the skin of the abdomen or thigh at least 45 minutes before sexual activity. The maximum is one dose per 24 hours and no more than eight doses per month.
The pt-141 dosage for women is the only one with FDA approval, and it is not weight-based. A pt-141 dosage calculator for women is not a substitute for the label; Vyleesi is a fixed 1.75 mg dose that does not need adjustment.
Bremelanotide is not FDA-approved for men. Any use in men is off-label and should be discussed with a clinician. Reports of 1–2 mg subcutaneously come from research forums, not from a controlled label.
PT-141 Dosage Chart: Injection, Research Peptide, and Nasal Spray
This pt-141 dosage chart compares the approved product with the off-label options people search for. The amounts below reflect clinical trial data or common research practice, not medical advice.
| Form | Typical dose | Timing | FDA status |
|---|---|---|---|
| Vyleesi autoinjector (subcutaneous) | 1.75 mg | 45 minutes before activity | Approved for premenopausal women with HSDD |
| Research peptide (10 mg vial, subcutaneous) | 1–2 mg | 30–60 minutes before | Not approved; research use only |
| Nasal spray (investigational) | 10 mg or 20 mg in older studies | 30–60 minutes before | Not approved; nasal development discontinued |
Most people searching for a pt-141 peptide dosage are looking at the middle row. A pt-141 peptide dosage chart helps with conversion math, but it cannot make an unapproved product safe or legal for human use.
PT-141 10 mg Vial: Reconstitution and Units
A 10 mg vial of PT-141 must be mixed with bacteriostatic water before injection. The amount of water you add determines the concentration, which is how people work out pt-141 dosage in ml and insulin syringe units.
| Water added | Concentration | 1 mg equals | 2 mg equals |
|---|---|---|---|
| 1 mL | 10 mg/mL | 10 units | 20 units |
| 2 mL | 5 mg/mL | 20 units | 40 units |
| 3 mL | 3.33 mg/mL | 30 units | 60 units |
Units above refer to a U-100 insulin syringe, where 100 units equal 1 mL. Online conversations about pt-141 10mg dosage for men usually describe a 10 mg vial reconstituted with 1–2 mL of water and injected at 1 mg to 2 mg. PT-141 sold as a research chemical is not tested for sterility, purity, or correct dosing in humans.
PT-141 Nasal Spray Dosage: What the Research Shows
Nasal bremelanotide was studied at 10 mg and 20 mg per dose in early trials. Those studies found meaningful blood pressure increases, and the nasal formulation was discontinued. No nasal PT-141 product is FDA-approved, so there is no official pt-141 nasal spray dosage.
People who buy nasal PT-141 online cannot know the actual concentration or purity. Intranasal dosing is also harder to measure consistently than a fixed autoinjector. For these reasons, nasal PT-141 is a research interest, not a recommended treatment.
Safety, Side Effects, and Who Should Avoid PT-141
Common side effects of bremelanotide include nausea, flushing, headache, and injection-site reactions. These effects are usually temporary but can be uncomfortable. A small number of users experience vomiting, which may reduce how well the drug works.
PT-141 can raise blood pressure. People with uncontrolled hypertension, known cardiovascular disease, or a history of stroke should not use bremelanotide. It should not be combined with alcohol or with medications that affect blood pressure without medical supervision.
Vyleesi carries a risk of focal hyperpigmentation, including darkening of the gums, face, or breasts. This side effect can be permanent and is more likely with repeated use. Anyone considering PT-141 should consult a healthcare professional and use only FDA-approved products when a prescription is appropriate.
Final Thoughts on PT-141 Dosing
The only FDA-approved PT-141 dosage is 1.75 mg subcutaneous Vyleesi, limited to one dose per 24 hours and eight doses per month. Research peptides and nasal sprays are not approved and carry unknown risks. Forum discussions about PT-141 dosing are anecdotal and are not evidence of safety or effectiveness.
Frequently Asked Questions
What is the standard PT-141 dosage?
The FDA-approved dose is 1.75 mg injected subcutaneously as Vyleesi, taken about 45 minutes before sexual activity. It should not be used more than once in 24 hours or more than eight times per month. Off-label research doses of 1–2 mg are not FDA-approved and may carry different risks.
How is a PT-141 10 mg vial dosed?
A 10 mg vial is typically reconstituted with 1–2 mL of bacteriostatic water, producing a concentration of 10 mg/mL or 5 mg/mL. At 10 mg/mL, 1 mg equals 10 units on a U-100 insulin syringe. Research peptides are not approved for human use and may not be sterile or accurately dosed.
Is there an FDA-approved PT-141 nasal spray dosage?
No. No nasal PT-141 product is FDA-approved, and the nasal bremelanotide formulation was discontinued after trials showed blood pressure increases. Older studies used 10 mg and 20 mg intranasal doses, but those amounts are not a recommended regimen.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.